Richard Gaster, M.D., Ph.D.

Oak Hill Bio is a clinical-stage biotech company committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

We are a clinical-stage biopharmaceutical company seeking to bring life into balance for patients suffering with Graves’ disease (GD) and thyroid eye disease (TED). We are led by a team with extensive experience in scientific innovation, clinical development and company building, and have a deep history of developing innovative treatments with the potential to make a significant impact on patients’ lives. Current treatments for GD and TED are very limited, and the ones available are associated with serious side effects that may restrict benefits or have long-term health impacts. Yarrow is developing YB-101, a potentially first-in-class inhibitor of the thyroid stimulating hormone receptor (TSHR), which directly disrupts the central autoimmune mechanism responsible for GD and TED. By directly binding to TSHR and protecting this receptor from autoantibody attack, YB-101 offers the potential to address both thyroidal and extra-thyroidal manifestations of these diseases without the risk of serious toxicities or immunosuppression, thereby delivering rapid, predictable control of these devastating autoimmune conditions.

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Biopharmaceutical company that designs and develops biologics for pulmonary hypertension & musculoskeletal disorders.

Entact Bio is developing a novel class of precision medicines that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitylase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has built its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs leverage the natural ability of DUBs to regulate and enhance protein function. By harnessing the power of DUBs, Entact is expanding the universe of treatable diseases and creating new options for patients who are underserved by current therapeutic modalities.

ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising product candidates. ACELYRIN is embedding a corporate culture of Courageous Caring™ -- placing patients first and embracing the concept that all of us are better than any one of us -- as we seek to addresses the most basic human needs: to live a productive life free from diseases.

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Our deep expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drugs through clinical trials. Our lead portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor, and VTX3232, a CNS-penetrant NLRP3 inhibitor. Our inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor, both of which have completed Phase 2 clinical trials.

Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.

Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted and highly selective small molecules to restore cellular metabolic quality control, thereby addressing the dysregulated growth and hyperactive signaling found in certain rare genetic and age-related diseases. Our lead development candidate, AV078, is a first-in-class CNS-penetrant selective mTORC1 inhibitor in Phase 2 development for refractory epilepsy associated with tuberous sclerosis complex (TSC), a rare genetic disorder driven by hyperactive mTORC1 signaling. Beyond AV078, we’ve developed a proprietary library of small molecules, which are potent and selective mTORC1 and CD38 inhibitors that have the potential to precisely target the underlying biology of multiple rare and age-related disease.

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.

InBrace is changing the face of orthodontics and revolutionizing orthodontic technology –– one mouth at a time. We’re transforming not only how teeth are adjusted, but the entire patient experience. How it works. How it feels. How it looks. Starting from day one. Because everyone deserves to feel confident sharing their truest selves with the world. Created by orthodontists, InBrace intelligently and intuitively moves teeth in a way that’s gentler, faster, and more discreet. Our decades of passion in this industry and our desire for complete patient satisfaction from the inside out are what guided us to challenge the status quo and create InBrace. We’re equally passionate about creating a company where talented, forward-thinking, collaborative individuals can thrive. Want to join us in our mission to change the face of this industry –– and the lives of patients around the world? We’d love to have you.

Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA. We are pioneering new territory, with an expedition led by a team of skilled scientists and drug development leaders who are inventive yet pragmatic. We are on a bold and exciting mission, a mission not without peril, but we have an energized, collaborative, creative and fearless team – a team that has consistently breached barriers and blazed new trails in search of solutions. We are now poised to realize the promise of bringing RNA into play for small-molecule drug discovery. Pushing the frontier of this emerging field of science is gratifying, but our mission goes beyond the thrill of scientific discovery. We believe that by targeting RNA biology in new ways, we have the potential to impact millions of patients. Our platform will allow us to reach hundreds of biological targets not currently accessible to medicine, including known targets previously considered “undruggable.” Our destination is powerful new therapies for patients everywhere, by opening up a new path for discovering RNA-targeted medicines.

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San Francisco.

At Harmony Biosciences, we specialize in developing and delivering treatments for rare neurological diseases. We believe that when empathy and innovation meet, a better life can begin for people living with neurological diseases. Our team of experts throughout the organization represent a wide variety of disciplines and experiences and are driven by the shared conviction that innovative science translates into therapeutic possibilities. We strive to take new therapies from the clinic to the medicine cabinet, providing support for patients, providers and the communities in which we live and work. Visit us: https://www.harmonybiosciences.com/ Follow us: @Harmonybio on Twitter View community guidelines: https://bit.ly/3KYPBSS

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics.

Oak Hill Bio is a clinical-stage biotech company committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

The Pediatric Brain Tumor Foundation is there for families facing the deadliest and most common childhood cancer, responding with resources and community support that address every family member’s needs. The largest patient advocacy funder of pediatric brain tumor research, PBTF also funds and advocates for innovative projects that lead to vital discoveries, new clinical trials, and better treatments – all bringing us closer to a cure.

We are a clinical-stage biopharmaceutical company seeking to bring life into balance for patients suffering with Graves’ disease (GD) and thyroid eye disease (TED). We are led by a team with extensive experience in scientific innovation, clinical development and company building, and have a deep history of developing innovative treatments with the potential to make a significant impact on patients’ lives. Current treatments for GD and TED are very limited, and the ones available are associated with serious side effects that may restrict benefits or have long-term health impacts. Yarrow is developing YB-101, a potentially first-in-class inhibitor of the thyroid stimulating hormone receptor (TSHR), which directly disrupts the central autoimmune mechanism responsible for GD and TED. By directly binding to TSHR and protecting this receptor from autoantibody attack, YB-101 offers the potential to address both thyroidal and extra-thyroidal manifestations of these diseases without the risk of serious toxicities or immunosuppression, thereby delivering rapid, predictable control of these devastating autoimmune conditions.

At Alumis, our goal is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights we derive from powerful data analytics to select the right target, right molecule, right indication, right patient, and right endpoint resulting in optimized outcomes for patients. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. Incubated by Foresite Labs, Alumis is led by a team of deeply experienced professionals who are devoted to transforming the lives of patients with immune-mediated diseases by developing a pipeline of transformative therapies.

Biopharmaceutical company that designs and develops biologics for pulmonary hypertension & musculoskeletal disorders.